Related Experiment Video

Updated: Apr 4, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

Isabelle Le Mercier1, J Louise Lines1, Randolph J Noelle1

  • 1Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth , Lebanon, NH , USA.

Frontiers in Immunology
|September 9, 2015
PubMed

Insights

Cancer immunotherapy using blocking antibodies against CTLA-4 and PD-1 shows promise. These negative checkpoint regulators can be targeted for cancer treatment and autoimmune disease therapies.

Area of Science:

  • Immunology
  • Oncology
  • Transplantation

Background:

  • Negative checkpoint regulators like CTLA-4 and PD-1 normally prevent autoimmunity.
  • These regulators also limit T cell responses against tumors.
  • Targeting these checkpoints offers new therapeutic strategies.

Purpose of the Study:

  • To review current knowledge on negative checkpoint regulators.
  • To discuss their role in cancer immunotherapy and autoimmune diseases.
  • To identify future targets for immunotherapy.

Main Methods:

  • Review of clinical trials involving blocking antibodies to CTLA-4 and PD-1.
  • Analysis of the role of negative checkpoint regulators in adaptive immune responses.
  • Discussion of potential combination therapies.

Main Results:

  • Blocking antibodies to CTLA-4 and PD-1 have shown significant promise in cancer immunotherapy.
  • Targeting these pathways can induce durable tolerance for autoimmune diseases and transplantation.
  • Future treatments may involve combination therapies for broader efficacy.

Conclusions:

  • Negative checkpoint regulators are critical targets for both cancer immunotherapy and the treatment of autoimmune diseases.
  • Further research into novel checkpoint regulators will expand therapeutic options.
  • Combination therapies hold potential for enhanced treatment outcomes.
Keywords:
BTLALAG-3TIGITTIM-3VISTAautoimmunitycancer immunotherapynegative checkpoint regulators

More Related Videos

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

25.0K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.7K

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.1K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
137.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K